Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients

Hepatology Research

Volumn 40, Issue 9, 2010, Pages 901-910

  Sumida, Yoshio ^a   Yonei, Yoshikazu ^b   Kanemasa, Kazuyuki ^a   Hara, Tasuku ^a   Inada, Yutaka ^a   Sakai, Kyoko ^a   Imai, Shunsuke ^a   Hibino, Sawako ^c   Yamaguchi, Kanji ^d   Mitsuyoshi, Hironori ^d   Yasui, Kohichiroh ^d   Minami, Masahito ^d   Itoh, Yoshito ^d   Naito, Yuji ^d   Yoshikawa, Toshikazu ^d   Okanoue, Takeshi ^e  

^a Nara City Hospital   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c Louis Pasteur Center for Medical Research   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Dehydroepiandrosterone; Fibrosis; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; PRASTERONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HISTOLOGY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 77956147855     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00704.x     Document Type: Article

References (47)

1. Ludwig J, Viggiano TR, McGill DB. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-8.
2. Matteoni CA, Younossi ZM, Gramlich T. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-19.
3. Rafiq N, Bai C, Fang Y. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-8.
4. Saibara T. Nonalcoholic steatohepatitis in Asia-Oceania. Hepatol Res 2005, 33:64-7.
5. Hamaguchi M, Kojima T, Takeda N. The Metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143:722-8.
6. Marcheisini G, Bugianesi E, Forlani G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-23.
7. Sanyal AJ, Campbell-Sargent C, Mirshahi F. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-92.
8. Oliveira CP, Costa Gayotto LC, Tatai C. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med 2002, 6:399-406.
9. Sumida Y, Nakashima T, Yoh T. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic liver disease. J Hepatol 2003, 38:32-8.
10. Roth GS, Lane MA, Ingram DK. Biomarkers of caloric restriction may predict longevity in humans. Science 2002, 297:811.
11. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986, 315:1519-24.
12. Bednarek-Tupikowska G, Gosk I, Szuba A. Influence of dehydroepiandrosterone on platelet aggregation, superoxide dismutase activity and serum lipid peroxide concentrations in rabbits with induced hypercholesterolemia. Med Sci Monit 2000, 6:40-5.
13. Lasco A, Frisina N, Morabito N. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001, 145:457-61.
14. Jakubowicz D, Beer N, Rengifo R. Effect of dehydroepiandrosterone on cyclic-guanosine monophosphate in men of advancing age. Ann NY Acad Sci 1995, 774:312-5.
15. Kawano M. Complement regulatory proteins and autoimmunity. Arch Immunol Ther Exp 2000, 48:367-72.
16. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005, 54:765-9.
17. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998, 273:32833-41.
18. Peters JM, Zhou YC, Ram PA. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol Pharmacol 1996, 50:67-74.
19. Charlton M, Angulo P, Chalasani N. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 2008, 47:484-92.
20. Kleiner DE, Brunt EM, Van Natta M. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-21.
21. New criteria of obesity (in Japanese). J Jpn Soc Study Obes 2000, 6:18-28. Japanese Society for the Study of Obesity
22. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-97. American Diabetes Association
23. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-19.
24. Katz A, Nambi SS, Mather K. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-10.
25. Brunt EM, Janney CG, Di Bisceglie AM. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-74.
26. Orentreich N, Brind JL, Vogelman JH. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992, 75:1002-4.
27. Chitturi S, Abeygunasekera S, Farrell GC. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-9.
28. Pagano G, Pacini G, Musso G. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35:367-72.
29. Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: evidence from literature. J Gastroenterol 2006, 41:725-32.
30. Boza C, Riquelme A, Ibañez L. Predictors of non-alcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005, 15:1148-53.
31. Nestler JE, Usiskin KS, Barlascini CO. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab 1989, 69:1040-6.
32. Celebi F, Yilmaz I, Aksoy H. Dehydroepiandrosterone prevents oxidative injury in obstructive jaundice in rats. J Int Med Res 2004, 32:400-5.
33. Goto H, Yamashita S, Makita T. Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats. Exp Anim 1998, 47:257-60.
34. Manco M, Bottazzo G. Does the hormone of eternal youth protect against nonalcoholic steatohepatitis? Hepatology 2008, 48:1351.
35. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practicalissues in their evaluation and management. Hepatology 2009, 49:306-17.
36. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46:582-9.
37. Litman HJ, Bhasin S, Link CL. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 2006, 91:4326-34.
38. Lookingbill DP, Demers LM, Wang C. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991, 72:1242-8.
39. Loria P, Carulli L, Bertolotti M. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009, 6:236-47.
40. Franz C, Watson D, Longcope C. Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis. Steroids 1979, 34:563-73.
41. Narasaka T, Moriya T, Endoh M. 17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver. Endocr J 2000, 47:697-705.
42. Elekima OT, Mills CO, Ahmad A. Reduced hepatic content of dehydroepiandrosterone sulphotransferase in chronic liver diseases. Liver 2000, 20:45-50.
43. Nair KS, Rizza RA, O'Brien P. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006, 355:1647-59.
44. Tsang SW, Ng WF, Wu BP. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2006, 21:116-21.
45. Wong VW, Wong GL, Chim AM. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008, 103:1682-8.
46. Ratziu V, Charlotte F, Heurtier A. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-906.
47. Merriman RB, Ferrell LD, Patti MG. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006, 44:874-80.